Becton, Dickinson and Company (BDX) to Release Quarterly Earnings on Monday

Becton, Dickinson and Company (NYSE:BDX) is anticipated to announce its Q1 2026 results before the market opens on Monday, February 9th. Analysts expect the company to announce earnings of $2.82 per share and revenue of $5.1521 billion for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, February 9, 2026 at 8:00 AM ET.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.92 by $0.04. The company had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.81 EPS. On average, analysts expect Becton, Dickinson and Company to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $210.45 on Friday. The stock has a market cap of $59.96 billion, a PE ratio of 36.10, a P/E/G ratio of 2.28 and a beta of 0.25. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The business’s 50-day simple moving average is $199.83 and its two-hundred day simple moving average is $192.22. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $235.34.

Becton, Dickinson and Company declared that its board has approved a share buyback program on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 2,463 shares of company stock worth $501,530 over the last quarter. Insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently modified their holdings of BDX. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company in the third quarter worth $25,000. Johnson Financial Group Inc. purchased a new stake in shares of Becton, Dickinson and Company in the third quarter valued at $33,000. Kelleher Financial Advisors purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth about $37,000. Wealth Watch Advisors INC bought a new position in Becton, Dickinson and Company during the 3rd quarter valued at about $48,000. Finally, Quarry LP grew its holdings in Becton, Dickinson and Company by 265.4% during the 3rd quarter. Quarry LP now owns 380 shares of the medical instruments supplier’s stock valued at $71,000 after purchasing an additional 276 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BDX shares. Stifel Nicolaus increased their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Royal Bank Of Canada raised their target price on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research note on Wednesday, December 17th. Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Bank of America increased their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Finally, Piper Sandler raised their price objective on Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a research report on Wednesday, January 28th. Five investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $213.36.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.